Does a patient's sex predict the efficacy of cancer immunotherapy?
A partir d'une revue systématique de la littérature publiée jusqu'en 2017 (20 essais randomisés, 11 351 patients atteints d'un cancer), cette méta-analyse évalue l'efficacité, selon le sexe des patients, des inhibiteurs de points de contrôle immunitaire (anti-PD1, anti-CTLA-4 tels que l'ipilimumab, le trémélimumab, le nivolumab, le pembrolizumab)
Cancer immunotherapy undoubtedly represents one of the most important advances in cancer treatment in the past decade.1,2 Among cancer immunotherapies, immune checkpoint inhibitors (including CTLA-4, PD-1, and PD-L1 inhibitors) have attracted the major share of attention of both physicians and patients. Several randomised trials have clearly proven the efficacy of these drugs in the management of several difficult-to-treat malignancies, including malignant melanoma, non-small-cell lung cancer, bladder cancer, and head and neck cancer, among many others.
The Lancet Oncology , commentaire, 2017